Welcome to BioSeeker Group!

Cancer Vaccines: Aim and Shoot

Additional Information

Published Date May 19, 2008
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 184
PDF Fact Sheet View Fact Sheet for the report Cancer Vaccines: Aim and Shoot in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Cancer Vaccines: Aim and Shoot.

    To find out more about Cancer Vaccines: Aim and Shoot, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Cancer Vaccines: Aim and Shoot is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. For the purposes of this report, BioSeeker is focusing on therapeutic cancer vaccines and as such the commercialized and pipeline prophylactic agents have not been included.

This report is written for you to identify your competition and understand which targeting strategies are at work within cancer vaccine drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed cancer vaccines and identified 75 drug targets belonging to 109 drugs. This report, Cancer Vaccine: Aim and Shoot, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer vaccine drugs.

In the report, BioSeeker reports on 66 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 109 cancer vaccine drugs designed for the treatment of 37 different cancer indications. The highest degree of distinctiveness among cancer vaccine drugs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of cancer vaccine drugs. No less than 64 protein-protein interactions were recognized among and between 41 of the 75 included cancer vaccine drug targets.

Why You Should Own Your Own Copy of this Report:

  • 180+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to related resources on the Internet
  • A 109 cancer vaccine drugs analysis, under development by 76 investigators, covering more than 236 developmental projects in cancer
  • 75 unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other drug targets, pursued cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
  • A unique drug target combination breakdown of cancer vaccines into tumor type, compound type, and developmental stage
  • Unique drug-protein target and protein-protein of drug targets interactome analysis
  • Pathway profiling of cancer vaccine drug targets
  • Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
  • Who are working on sequels to blockbuster drugs?
  • Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 4.1 List of Figures
4.2 List of Tables
5 How to Use this Report
6 Cancer Vaccines Types
7 The Cancer Genome Project and Cancer Vaccine Drug Targets
7.1 Cancer Vaccine Drug Targets Present in the Cancer Gene Census and in the Catalogue of
Somatic Mutations in Cancer
8 Protein Expression Profiles of Cancer Vaccine Drug Targets in Human
8.1 Expression in Normal Tissues and Cancer Tissues
8.2 Expression in Human Cancer Cell Lines and Primary Cells
9 Pathway Analysis of Cancer Vaccine Drugs
10 Protein-Protein Interactions Among Identified Cancer Vaccine Drug Targets
11 Available Biological Structure Data on Cancer Vaccine Drug Targets
12 Drug Target Profiles of Cancer Vaccine Drug Targets in Oncology
12.1.1 Acid phosphatase activity
12.1.2 Carboxypeptidase activity
12.1.3 Catalytic activity
12.1.4 Cell adhesion molecule activity
12.1.5 Chaperone activity
12.1.6 Cofactor binding
12.1.7 Complement activity
12.1.8 Cytokine activity
12.1.9 DNA binding
12.1.10 DNA topoisomerase activity
12.1.11 DNA-directed DNA polymerase activity
12.1.12 Growth factor activity
12.1.13 Hormone activity
12.1.14 Hydrolase activity
12.1.15 Intracellular ligand-gated ion channel activity
12.1.16 Kinase binding
12.1.17 Kinase regulator activity
12.1.18 Metallopeptidase activity
12.1.19 MHC class I receptor activity
12.1.20 Molecular function unknown
12.1.21 Oxidoreductase activity
12.1.22 Peptidase activity
12.1.23 Peptide hormone
12.1.24 Protein binding
12.1.25 Protein serine/threonine kinase activity
12.1.26 Protein-tyrosine kinase activity
12.1.27 Receptor activity
12.1.28 Receptor binding
12.1.29 Receptor signaling complex scaffold activity
12.1.30 RNA-directed DNA polymerase activity
12.1.31 Serine-type peptidase activity
12.1.32 T cell receptor activity
12.1.33 Transcription factor activity
12.1.34 Transmembrane receptor activity
12.1.35 Transmembrane receptor protein tyrosine kinase activity 12.1.36 Transporter activity
12.1.37 Viral Protein
13 The Drug-Protein Interactome of Cancer Vaccines
14 The Progression and Maturity of Cancer Vaccine Drug Target Combinations
14.1 Target Profiles of Cancer Vaccines in Pre-Registration or on the Market
14.2 New Cancer Vaccine Target Combinations in Phase III Clinical Development
14.3 New Cancer Vaccine Target Combinations in Phase II Clinical Development
14.4 New Cancer Vaccine Target Combinations Phase I Clinical Development
14.5 New Cancer Vaccine Target Combinations in Preclinical Development
14.6 Development Profiles of All Identified Cancer VaccineTarget Combinations
15 Cancer Vaccine Drug Target Mix by Cancer Indication
15.1 Anal Dysplasia
15.2 Basal Cell Cancer
15.3 Bladder Cancer
15.4 Bone Cancer
15.5 Brain Cancer
15.6 Breast Cancer
15.7 Cervical Cancer
15.8 Cervical Dysplasia
15.9 Chemotherapy-Induced Bone Marrow Injury
15.9.1 Chemotherapy-Induced Neutropenia
15.10 Colorectal Cancer
15.11 Gastrointestinal Cancer
15.12 Head and Neck Cancer
15.13 Leukemia
15.13.1 Acute Myelogenous Leukemia
15.13.2 Chronic Lymphocytic Leukemia
15.13.3 Chronic Myelogenous Leukemia
15.14 Liver Cancer
15.15 Lung Cancer
15.15.1 Non-Small Cell Lung Cancer
15.15.2 Small Cell Lung Cancer
15.16 Lymphoma
15.16.1 B-Cell Lymphoma
15.16.2 Non-Hodgkin’s Lymphoma
15.16.3 T-Cell Lymphoma
15.17 Myelodysplastic Syndrome
15.18 Myeloma
15.19 Nasopharyngeal Cancer
15.20 Oesophageal Cancer
15.21 Ovarian Cancer
15.22 Pancreatic Cancer
15.23 Prostate Cancer
15.24 Renal Cancer
15.25 Sarcoma
15.26 Skin Cancer
15.26.1 Melanoma
15.27 Thyroid Cancer
16 Cancer Vaccine Drugs and Their Targets by Companies
16.1 Australia
16.2 Canada
16.3 China
16.4 Denmark
16.5 France
16.6 Germany
16.7 India
16.8 Israel
16.9 Italy
16.10 Japan
16.11 Netherlands
16.12 Norway
16.13 South Korea
16.14 Switzerland
16.15 United Kingdom
16.16 USA
16.17 Non-Industrial Bodies
17 Disclaimer
18 Drug Index
19 Company Index
4.1 List of Figures
Figure 1: Distribution of Compound Types Among Cancer Vaccines
Figure 2: Primary Sub-cellular Localization of Drug Targets
Figure 3: Visualization of Protein-Protein Interactions Among Cancer Vaccine Drug Targets
Figure 4: The Vaccine-Protein Interactome of Cancer Vaccines
Figure 5: Direct Head-to-Head Targeting Interactome of Cancer Vaccines
4.2 List of Tables
Table 2: Drug Targets of Cancer Vaccines Present in the Catalogue of Somatic Mutations in Cancer and in the
Cancer Gene Census
Table 3: Available Protein Expression Profiles of Cancer Vaccine Drug Targets
Table 4: Pathway Summary
Table 5: Drug Targets Without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of Cancer Vaccine Targets
Table 7: Pathway Profile According to KEGG of Cancer Vaccine Targets
Table 8: Cancer Vaccines Targeting Major Singaling Pathways
Table 9: Protein-Protein Interactions Among Cancer Vaccine Drug Targets
Table 10: Number of Available Biological Structures on Cancer Vaccine Targets
Table 11: Overview of Drug Target Profile Themes
Table 12: Vaccine-Protein Target Clusters in the Cancer Vaccine Drug Target Interactome
Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the
Presence of New Drug Target Mixes by Developmental Stage
Table 14: Target Profiles of Cancer Vaccines in Pre-Registration or on the Market
Table 15: New Cancer Vaccine Drug Target Combinations in Phase III Clinical Development
Table 16: New Cancer Vaccine Target Combinations in Phase II Clinical Development
Table 17 New Cancer Vaccine Target Combinations Phase I Clinical Development
Table 18: New Cancer Vaccine Target Combinations in Preclinical Development
Table 19: Top 5 Pursued Cancer Vaccine Targets
Table 20: The Progression, Maturity and Comptitive Comparison of Cancer Vaccine Target Mixes in
Development
Table 21: Number of Cancer Vaccine Drug Target Mixes Reported by Cancer Indication
Table 22: Locating Your Competitors/Peers - Step 1
Table 23: Locating Your Competitors/Peers - Step 2
Table 24: Drug Targets of Cancer Vaccines for the Treatment of Anal Dysplasia According to the Compound Type
and Developmental Stage of Vaccine
Table 25: Drug Targets of Cancer Vaccines for the Treatment of Basal Cell Cancer According to the Compound
Type and Developmental Stage of Vaccine
Table 26: Drug Targets of Cancer Vaccines for the Treatment of Bladder Cancer According to the Compound
Type and Developmental Stage of Vaccine
Table 27: Drug Targets of Cancer Vaccines for the Treatment of Bone Cancer According to the Compound Type
and Developmental Stage of Vaccine
Table 28: Drug Targets of Cancer Vaccines for the Treatment of Brain Cancer According to the Compound Type
and Developmental Stage of Vaccine
Table 29: Drug Targets of Cancer Vaccines for the Treatment of Breast Cancer According to the Compound Type
and Developmental Stage of Vaccine
Table 30: Drug Targets of Cancer Vaccines for the Treatment of Cervical Cancer According to the Compound
Type and Developmental Stage of Vaccine
Table 31: Drug Targets of Cancer Vaccines for the Treatment of Cervical Dysplasia According to the Compound
Type and Developmental Stage of Vaccine
Table 32: Drug Targets of Cancer Vaccines for the Treatment of Chemotherapy-Induced Bone Marrow Injury
(General) According to the Compound Type and Developmental Stage of Vaccine
Table 33: Drug Targets of Cancer Vaccines for the Treatment of Chemotherapy-Induced Neutropenia According
to the Compound Type and Developmental Stage of Vaccine
Table 34: Drug Targets of Cancer Vaccines for the Treatment of Colorectal Cancer According to the Compound
Type and Developmental Stage of Vaccine
Table 35: Drug Targets of Cancer Vaccines for the Treatment of Gastrointestinal Cancer According to the
Compound Type and Developmental Stage of Vaccine
Table 36: Drug Targets of Cancer Vaccines for the Treatment of Head and Neck Cancer According to the
Compound Type and Developmental Stage of Vaccine
Table 37: Drug Targets of Cancer Vaccines for the Treatment of Leukemia (General) According to the Compound
Type and Developmental Stage of Vaccine
Table 38: Drug Targets of Cancer Vaccines for the Treatment of Acute Myelogenous Leukemia According to the
Compound Type and Developmental Stage of Vaccine
Table 39: Drug Targets of Cancer Vaccines for the Treatment of Chronic Lymphocytic Leukemia According to the
Compound Type and Developmental Stage of Vaccine
Table 40: Drug Targets of Cancer Vaccines for the Treatment of Chronic Myelogenous Leukemia According to
the Compound Type and Developmental Stage of Vaccine
Table 41: Drug Targets of Cancer Vaccines for the Treatment of Liver Cancer According to the Compound Type
and Developmental Stage of Vaccine
Table 42: Drug Targets of Cancer Vaccines for the Treatment of Lung Cancer (General) According to the
Compound Type and Developmental Stage of Vaccine
Table 43: Drug Targets of Cancer Vaccines for the Treatment of Non Small Cell Lung Cancer According to the
Compound Type and Developmental Stage of Vaccine
Table 44 Drug Targets of Cancer Vaccines for the Treatment of Small Cell Lung According to the Compound Type
and Developmental Stage of Vaccine
Table 45: Drug Targets of Cancer Vaccines for the Treatment of Lymphoma (General) According to the
Compound Type and Developmental Stage of Vaccine
Table 46: Drug Targets of Cancer Vaccines for the Treatment of B-Cell Lymphoma According to the Compound
Type and Developmental Stage of Vaccine
Table 47: Drug Targets of Cancer Vaccines for the Treatment of non-Hodgkin’s Lymphoma According to the
Compound Type and Developmental Stage of Vaccine
Table 48: Drug Targets of Cancer Vaccines for the Treatment of T-Cell Lymphoma According to the Compound
Type and Developmental Stage of Vaccine
Table 49: Drug Targets of Cancer Vaccines for the Treatment of Myelodysplastic Syndrome According to the
Compound Type and Developmental Stage of Vaccine
Table 50: Drug Targets of Cancer Vaccines for the Treatment of Myeloma According to the Compound Type and
Developmental Stage of Vaccine
Table 51: Drug Targets of Cancer Vaccines for the Treatment of Nasopharyngeal Cancer According to the
Compound Type and Developmental Stage of Vaccine
Table 52: Drug Targets of Cancer Vaccines for the Treatment of Oesophageal Cancer According to the
Compound Type and Developmental Stage of Vaccine
Table 53: Drug Targets of Cancer Vaccines for the Treatment of Ovarian Cancer According to the Compound
Type and Developmental Stage of Vaccine
Table 54: Drug Targets of Cancer Vaccines for the Treatment of Pancreatic Cancer According to the Compound
Type and Developmental Stage of Vaccine
Table 55: Drug Targets of Cancer Vaccines for the Treatment of Prostate Cancer According to the Compound
Type and Developmental Stage of Vaccine
Table 56: Drug Targets of Cancer Vaccines for the Treatment of Renal Cancer According to the Compound Type
and Developmental Stage of Vaccine
Table 57: Drug Targets of Cancer Vaccines for the Treatment of Sarcoma According to the Compound Type and
Developmental Stage of Vaccine
Table 58: Drug Targets of Cancer Vaccines for the Treatment of Skin Cancer According to the Compound Type
and Developmental Stage of Vaccine
Table 59: Drug Targets of Cancer Vaccines for the Treatment of Melanoma According to the Compound Type
and Developmental Stage of Vaccine
Table 60: Drug Targets of Cancer Vaccines for the Treatment of Thyroid Cancer According to the Compound
Type and Developmental Stage of Vaccine
Table 61: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Australia
Table 62: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Canada
Table 63: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in China
Table 64: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Denmark
Table 65: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in France
Table 66: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Germany
Table 67: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in India
Table 68: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Israel
Table 69: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Italy
Table 70: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Japan
Table 71: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in the Netherlands
Table 72: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Norway
Table 73: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in South Korea
Table 74: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Switzerland
Table 75: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in United Kingdom
Table 76: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in USA
Table 77: Cancer Vaccines with Drug Target Mix and Developmental Projects by Non-Industrial Bodies

This report covers in-depth the following 71 investigators:
AC Immune
Advaxis
Agensys
Aida Pharmaceuticals
Alexion
AlphaVax
AMDL
Apthera
AstraZeneca
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
BioVex
Cadila
Cancer Research Technology
Cell Genesys
Cel-Sci
CG Therapeutics
Coley
Cosmo Pharmaceuticals
CSL
Dendreon
DynPort Vaccine Company
EntreMed
Epeius Biotechnologies
Generex
GenOdyssee Pharmaceuticals
GenVec
Geron
GlaxoSmithKline
GlobeImmune
Ichor Medical Systems
Idera Pharmaceuticals
ImmunoFrontier
Immunotope
Inovio
Introgen Therapeutics
Medarex
Medical Marketing International
Merck KGaA
MGI Pharma
Micromet
MolMed
Mologen
Neovacs
Nventa
Oncothyreon
Oncovir
Onyvax
Oxford BioMedica
Pepscan
Pfizer
Pharmexa
Point Therapeutics
Prima Biomed
Progenics Pharmaceuticals
Receptor BioLogix
responsif
SciClone Pharmaceuticals
TapImmune
Therion Biologics
Transgene
Vaccinex
Vaxil BioTherapeutics
Vaxon Biotech
Vical
Viragen
Virionics
ViroMed
Zensun
Includes a total of 109 cancer vaccines drugs in oncology.
Some examples are:
Allovectin-7
CDX-110
E-75
egr1-TNF-alpha gene therapy
Gastrimmune
GV-1001
GVAX
ipilimumab
MAGE-A3 vaccine
sargramostim
Stimuvax
thymalfasin
TroVax
verpasep caltespen

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Cancer Vaccines: Aim and Shoot.
    To find out more about Cancer Vaccines: Aim and Shoot, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Cancer Vaccines: Aim and Shoot is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer. Learn More


Strategic Outlook on Protein Kinase Inhibitors in Oncology
A strategic outlook on protein kinase inhibitors in oncology. Including targets, indictions and competitive assessment. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More


Leukemia - A Therapeutic & Competitive Insight
In the report "Leukemia - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to understand the complex field of leukemia therapeutics. Learn More

Other selected research from the 'Vaccines' category:


Cancer Vaccines: Aim and Shoot
This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. Learn More


The Complete Guide to Targeted Therapies in Oncology: A World Review
In this comprehensive report covering targeted therapies in oncology, BioSeeker Group has analyzed apoptopic agents, protein kinase inhibitors, anti-angiogenic and vascular targeting agents, immunostimulators, antibodies and vaccines in oncology. Learn More